Introduction
Ketamine's side effect profile is fundamentally different from that of conventional psychiatric and analgesic medications. Where SSRIs produce gradual-onset side effects that persist for days to weeks, and opioids carry risks of respiratory depression and constipation, ketamine produces a distinctive constellation of acute, time-limited effects that resolve within hours of each treatment session. Understanding this profile in detail is essential for clinicians prescribing or administering ketamine, for developing informed consent documents, and for counseling patients who may be unfamiliar with the dissociative experience.
This article provides a comprehensive, evidence-based review of the side effects observed during low-dose (subanesthetic) ketamine therapy, organized by system, with attention to incidence rates, mechanisms, risk factors, and management strategies. The focus is on the 0.5 mg/kg IV infusion paradigm and equivalent doses by other routes, as these represent the most common clinical applications.
Dissociative Symptoms
Phenomenology and Incidence
Dissociation is the signature pharmacological effect of ketamine and the side effect most unfamiliar to patients and clinicians experienced primarily with conventional therapeutics. At the standard antidepressant dose of 0.5 mg/kg IV over 40 minutes, dissociative symptoms of at least mild intensity occur in approximately 60 to 80 percent of patients.
The dissociative experience encompasses a spectrum of phenomena: derealization (the environment feels unreal or dreamlike), depersonalization (a sense of detachment from one's own body or thoughts), altered time perception (time may feel slowed, accelerated, or suspended), ego dissolution (blurring of the boundary between self and environment), and perceptual distortions (objects may appear larger, smaller, or differently colored). Patients commonly describe the experience as "floating," "being in a dream," or "watching myself from a distance."
Clinical Significance
An important and still-debated question is whether dissociation is merely a side effect or an active component of ketamine's therapeutic mechanism. Several studies have found positive correlations between dissociation intensity (measured by the Clinician-Administered Dissociative States Scale, or CADSS) and antidepressant response magnitude. However, other studies have failed to replicate this association, and the question remains unresolved.
Regardless of its mechanistic role, dissociation is the primary source of patient anxiety about ketamine treatment. Thorough pre-treatment counseling that normalizes the experience, provides concrete descriptions of what to expect, and reassures patients that the effects are time-limited dramatically reduces distress during treatment.
Time Course and Resolution
Dissociative symptoms typically begin within 5 to 10 minutes of initiating IV infusion, peak at 15 to 30 minutes (often coinciding with the mid-infusion period), and resolve within 60 to 90 minutes of infusion completion. Sublingual and oral routes produce a more gradual onset and longer duration of milder dissociative effects. By two hours post-treatment, fewer than 5 percent of patients report any residual dissociative symptoms.
Management
For patients who find dissociation distressing, clinicians have several options. Reducing the infusion rate (extending from 40 to 50 or 60 minutes) attenuates peak dissociative intensity without substantially compromising efficacy. Dose reduction (to 0.4 or 0.35 mg/kg) decreases dissociation but may also reduce therapeutic benefit. Environmental modifications -- eye masks, calming music through headphones, dimmed lighting, and the reassuring presence of a trained staff member -- help many patients tolerate the experience comfortably.
Pretreatment with low-dose benzodiazepines (such as midazolam 1 to 2 mg or lorazepam 0.5 mg) reduces dissociation but has been associated with attenuated antidepressant response in some studies, making this approach controversial. If benzodiazepines are used, the lowest effective dose should be employed, and clinical response should be closely monitored for any attenuation.
Nausea and Vomiting
Incidence and Mechanisms
Nausea is the second most common side effect of low-dose ketamine, occurring in approximately 15 to 30 percent of patients receiving IV infusions. Vomiting is less frequent, reported in 5 to 10 percent. The mechanisms are multifactorial: direct stimulation of dopaminergic and serotonergic receptors in the chemoreceptor trigger zone (CTZ), vestibular disturbance secondary to the dissociative state, and autonomic activation related to ketamine's sympathomimetic properties.
Risk factors for nausea include female sex, history of motion sickness, prior postoperative nausea and vomiting, younger age, and non-fasting state before treatment. Oral and sublingual administration routes produce higher nausea rates than IV due to additional gastrointestinal mucosal irritation.
Prevention and Treatment
Prophylactic ondansetron 4 mg administered 30 minutes before the infusion is the first-line antiemetic strategy, reducing nausea incidence by approximately 40 to 60 percent in high-risk patients. Patients should be advised to fast for two to four hours before treatment. Non-pharmacological measures including supine positioning, minimal head movement, cool environment, and reduced sensory stimulation are effective adjuncts. For a detailed discussion of nausea management, see the managing nausea guide.
Cardiovascular Effects
Blood Pressure and Heart Rate Changes
Ketamine is a sympathomimetic agent that releases catecholamines and inhibits neuronal catecholamine reuptake. At subanesthetic doses, this produces clinically significant but usually well-tolerated hemodynamic changes. Typical findings during a 0.5 mg/kg IV infusion include systolic blood pressure elevation of 15 to 25 mmHg, diastolic blood pressure elevation of 10 to 15 mmHg, and heart rate increase of 10 to 20 beats per minute. These changes peak during or shortly after the infusion and return to baseline within 60 to 120 minutes.
Clinical Implications
The cardiovascular effects of ketamine necessitate structured vital sign monitoring. Standard protocols include measurements at baseline, every 15 minutes during infusion, and every 30 minutes for one to two hours post-infusion. Patients with baseline systolic blood pressure above 170 mmHg or diastolic above 100 mmHg are generally excluded from treatment or require antihypertensive optimization before proceeding.
Rare cases of hypertensive urgency have been reported, and clinics should have protocols for acute blood pressure management available, including agents such as labetalol or hydralazine. Notably, ketamine does not produce the orthostatic hypotension common to many psychiatric medications, which can be an advantage in populations susceptible to falls.
Cardiac Rhythm Considerations
At subanesthetic doses, clinically significant arrhythmias are extremely rare. Ketamine does not significantly prolong the QTc interval at therapeutic doses, distinguishing it from several other psychiatric medications. Patients with known structural heart disease, congestive heart failure, or a history of arrhythmia should receive cardiology clearance before initiating ketamine therapy, though these conditions are not absolute contraindications at low doses.
Perceptual Disturbances
Visual and Auditory Changes
Beyond the dissociative experience, patients frequently report a range of sensory-perceptual changes during ketamine administration. Visual effects include blurred vision, enhanced or altered color perception, geometric pattern perception, and apparent movement or "breathing" of stationary objects. Auditory effects include muffled hearing, altered sound quality, echoing of voices, or increased sensitivity to environmental sounds.
These perceptual disturbances are reported by 40 to 60 percent of patients and reflect ketamine's modulation of sensory processing at thalamic and cortical levels. They are distinct from true hallucinations in that patients typically retain awareness that the perceptions are drug-induced rather than reality-based. However, at higher doses or in susceptible individuals, more vivid phenomena approaching formed visual or auditory hallucinations can occur and should prompt dose reassessment.
Somatosensory Effects
Numbness, tingling, and heaviness or lightness in the extremities are commonly reported during and immediately after infusion. These effects result from ketamine's NMDA receptor blockade in somatosensory cortex and are self-limiting. Patients should be counseled that transient numbness and unusual body sensations are expected and do not indicate a neurological problem.
Cognitive Effects
Acute Cognitive Impairment
During and for several hours after ketamine administration, patients experience measurable cognitive impairment affecting attention, working memory, executive function, and processing speed. This impairment is dose-dependent and resolves within two to four hours for most patients, with some residual slowing persisting for up to 24 hours.
The acute cognitive effects are the primary basis for universal recommendations that patients not drive, operate machinery, make important financial or legal decisions, or sign binding documents for at least 24 hours following treatment. Patients receiving at-home oral formulations must be counseled with equal rigor about these restrictions.
Longer-Term Cognitive Considerations
Studies of therapeutic ketamine have not demonstrated progressive cognitive decline over treatment courses of six to twelve months. This contrasts with findings in chronic recreational users, who show dose-dependent impairments in episodic memory and executive function. The difference likely reflects the much lower doses and frequencies used therapeutically. Nevertheless, periodic cognitive screening is prudent for patients on long-term maintenance therapy, particularly older adults.
Psychiatric Side Effects
Anxiety and Dysphoria
A subset of patients (approximately 10 to 20 percent) experience transient anxiety, agitation, or dysphoria during ketamine infusion, particularly during the onset phase when the unfamiliar dissociative experience is first perceived. This is most common in treatment-naive patients and in those with comorbid anxiety disorders.
Pre-treatment anxiety management begins with education and expectation-setting. A calm, private treatment environment with consistent staff provides reassurance. For patients with severe anticipatory anxiety, a brief anxiolytic premedication (such as hydroxyzine 25 mg) can be considered, with the caveat that benzodiazepines may attenuate therapeutic response.
Euphoria and Abuse Potential
Ketamine can produce feelings of euphoria, well-being, and interconnectedness during administration. While these effects are generally brief, they contribute to ketamine's abuse potential and require clinical awareness. Most patients receiving therapeutic ketamine do not develop problematic patterns, but those with current or past substance use disorders warrant closer monitoring and more structured treatment protocols, including directly observed administration and urine drug screening.
Emergence Phenomena
Emergence reactions -- vivid, sometimes frightening mental experiences during recovery from ketamine's acute effects -- are well-documented in anesthetic practice and can occur at subanesthetic doses, though less commonly. These may include vivid imagery, a sense of impending doom, confusion, or agitation. Emergence phenomena are more common with rapid IV administration and at higher doses. A calm recovery environment with patient reassurance is usually sufficient management.
Urological Effects
Ketamine-Associated Cystitis
Long-term, high-frequency ketamine use is associated with a distinctive inflammatory cystitis characterized by bladder pain, urinary frequency and urgency, dysuria, and hematuria. In severe cases, contracted bladder with markedly reduced capacity can occur. This complication is primarily documented in recreational users consuming multiple grams daily over months to years.
At therapeutic doses and frequencies, clinically significant cystitis is rare but not absent from case reports -- see the full review of ketamine bladder safety. Clinicians should inquire about lower urinary tract symptoms at each follow-up visit and maintain a low threshold for urological referral in patients reporting new urinary complaints. Early detection and dose modification can prevent progression.
Hepatic Effects
Liver Function Changes
Chronic ketamine exposure can elevate hepatic transaminases and, rarely, produce cholestatic liver injury. Routine liver function monitoring (every three to six months during maintenance therapy) is recommended. Patients with pre-existing hepatic disease may require more cautious dosing and frequent monitoring.
Other Effects
Headache
Post-treatment headache occurs in approximately 15 to 25 percent of patients, typically mild to moderate in intensity and responsive to standard analgesics (acetaminophen, NSAIDs). Headache tends to decrease with successive treatments as patients become accustomed to the hemodynamic and neurochemical changes associated with infusion.
Fatigue and Drowsiness
Post-infusion fatigue is reported by 20 to 30 percent of patients. Most patients prefer to rest for one to two hours following treatment. Some patients describe a paradoxical sense of energization after the initial fatigue resolves, possibly related to acute mood improvement.
Dizziness and Ataxia
Dizziness, imbalance, and gait unsteadiness are common during the immediate post-infusion period and reflect ketamine's effects on vestibular and cerebellar function. Patients should remain seated or supervised when standing until these effects fully resolve, typically within 60 to 90 minutes. Fall prevention measures (low treatment chairs, staff assistance for ambulation) are standard clinic precautions.
Increased Salivation
Ketamine increases salivary secretions through its effects on muscarinic receptors. While not typically problematic at subanesthetic doses, some patients find excess salivation uncomfortable. Glycopyrrolate 0.2 mg IV can be used as a drying agent if needed, though this is rarely necessary at low doses.
Pre-Treatment Counseling Framework
Effective side effect management begins before the first treatment. A structured counseling framework should cover the following points:
What they will feel: Describe the dissociative experience in concrete, non-alarming terms. Phrases like "floating sensation," "dreamlike quality," and "things may seem distant or slightly unreal" are more helpful than clinical terminology.
What is normal: Explicitly list the common side effects (altered perceptions, mild nausea, blood pressure elevation, cognitive slowing) and emphasize their transient nature.
What to do if uncomfortable: Reassure patients that staff are continuously present, that the infusion can be slowed or paused at any time, and that anti-nausea medication is available immediately if needed.
After-treatment restrictions: Clearly communicate the 24-hour prohibition on driving, machinery operation, and important decision-making. Require that patients arrange transportation home.
When to contact the clinic: Provide specific guidance on what symptoms warrant a call (persistent headache beyond 24 hours, urinary changes, mood worsening, or any symptom that concerns the patient).
Monitoring Protocol Summary
A standardized monitoring protocol should include the following at minimum: vital signs (blood pressure, heart rate, respiratory rate, oxygen saturation) at baseline, every 15 minutes during infusion, and every 30 minutes post-infusion until discharge criteria are met. Dissociation assessment using the CADSS or a simplified clinical rating at peak effect. Side effect documentation using a checklist or severity scale at each visit. Discharge criteria: oriented to person, place, and time; ambulatory without assistance; blood pressure within 20 percent of baseline; no active nausea or vomiting; responsible adult present for transport home.
References
- PubMed: Side Effects of Ketamine in Depression Treatment: A Systematic Review (Short et al., 2018) — Comprehensive systematic review quantifying side effect incidence across ketamine depression trials
- PubMed: Consensus Guidelines for IV Ketamine Infusions in Chronic Pain (Cohen et al., 2018) — Expert consensus on monitoring, side effect management, and safety parameters during ketamine infusions
- PubMed: Cardiovascular Effects of Subanesthetic Ketamine (Wan et al., 2015) — Clinical analysis of hemodynamic changes during low-dose ketamine administration
- FDA: Spravato (Esketamine) Prescribing Information and REMS — FDA-approved labeling with comprehensive adverse event data from pivotal esketamine trials
- NIH NIMH: Ketamine as a Rapid-Acting Antidepressant — National Institute of Mental Health overview of ketamine research including safety and tolerability data
- PubMed: Dissociative Symptoms and Antidepressant Response to Ketamine (Luckenbaugh et al., 2014) — Study examining the relationship between acute dissociation and antidepressant efficacy
Share